CATALYST PHARMACEUTICA

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

09 Aug 2023 15:17:05 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

19 Jul 2023 05:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

20 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

01 Jun 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

30 May 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

10 May 2023 15:28:05 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

09 May 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

01 May 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

24 Apr 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

20 Apr 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

15 Mar 2023 15:11:45 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

08 Mar 2023 10:20:58 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

01 Mar 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day

22 Feb 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

07 Feb 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

25 Jan 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

23 Jan 2023 12:25:09 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

23 Jan 2023 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

19 Dec 2022 15:10:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

09 Nov 2022 15:11:31 By Nasdaq GlobeNewswire